HC Wainwright downgraded shares of IO Biotech (NASDAQ:IOBT – Free Report) from a buy rating to a neutral rating in a report released on Monday morning, MarketBeat Ratings reports. Wall Street Zen upgraded shares of IO Biotech to a “sell” rating in a report on Saturday, June 14th. Get IO Biotech alerts:View Our Latest Research Report on IOBTIO Biotech Trading Down 76.9%NASDAQ:IOBT opened at $0.37 on Monday. IO Biotech Company Profile(Get Free Report)IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. Further ReadingReceive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.